Successful treatment of a high-risk nonseminomatous germ cell tumor using etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine: A case report
作者机构：Department of Internal MedicineDivision of Hematology-OncologySoonchunhyang University Bucheon HospitalSoonchunhyang University School of MedicineBucheon 14584South Korea Department of Urology and Internal MedicineSoonchunhyang University Bucheon HospitalSoonchunhyang University School of MedicineBucheon 14584South Korea
出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)
年 卷 期：2020年第8卷第21期
页 面：5334-5340页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：Supported by the Soonchunhyang University Research Fund No.20200011
主 题：Antineoplastic combined chemotherapy protocols Choriocarcinoma Testicular neoplasms Cyclophosphamide Methotrexate Case report
摘 要：BACKGROUND Choriocarcinoma is an infrequent entity and the most aggressive subtype of germcell *** of early metastatic spread and rapid disease progression,choriocarcinoma patients display poor *** etoposide,methotrexate,actinomycin D,cyclophosphamide,and vincristine(EMA-CO)regimen is widely used to treat gestational trophoblastic tumors in females,its role in treating male choriocarcinoma is seldom *** SUMMARY A 32-year-old man was diagnosed with burned-out primary germ cell tumors(GCT)with retroperitoneum,liver and lung *** of the liver revealed pure *** patient received bleomycin,etoposide,and cisplatin *** two cycles of treatment,response evaluation revealed the mixed ***-CO regimen was used in the second-line *** eight cycles,the patient showed a potentially resectable state and thus,all residual masses were surgically *** patient was completely cured,and 10 years later,he is leading a healthy life without *** This paper is the first case of high-risk nonseminomatous GCT in a male patient to be successfully treated with the EMA-CO *** EMA-CO regimen can be used actively in patients with high-risk nonseminomatous GCT.
维普期刊数据库